istock-518308224_leventince
leventince / iStockphoto.com
4 July 2018Americas

LSIPR 50 2018: It’s not like selling cars

Managing and licensing the IP portfolio of a biomedical research centre as prestigious as the Broad Institute of MIT and Harvard may come with any number of challenges, but for Issi Rozen there is one key question he tackles in his day-to-day work as chief business officer: how can the Broad’s proprietary technology have the maximum impact possible, in a responsible way?

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
10 June 2026   Valuable antibody technology, a former employee, and a dispute over patent rights extending across the US, Europe and Asia at the heart of the latest suit.
Americas
9 June 2026   A unanimous SCOTUS ruling is being hailed as a major win for Hikma, and for delivering some welcome clarity. Experts tell Marisa Woutersen how its implications could affect pharma patent strategy across the sector.
Americas
8 June 2026   Nexus Pharmaceuticals is knocked back by the US Court of Appeals, which upholds a district court finding that it infringed a rival’s patents.